HIV-1 resistance to the capsid-targeting inhibitor PF74 results in altered dependence on host factors required for virus nuclear entry

Journal of Virology

Volumn 89, Issue 17, 2015, Pages 9068-9079

  Zhou, Jing ^a   Price, Amanda J ^b   Halambage, Upul D ^a   James, Leo C ^b   Aiken, Christopher ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; PF 74; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHAPERONE; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; CLEAVAGE FACTOR IM, HUMAN; INDOLE DERIVATIVE; KARYOPHERIN BETA; NUCLEOPORIN; NUP153 PROTEIN, HUMAN; PF-3450074; PHENYLALANINE; PROTEIN BINDING; RAN-BINDING PROTEIN 2; SMALL INTERFERING RNA; TNPO3 PROTEIN, HUMAN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL NUCLEUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; AMINO ACID SUBSTITUTION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BINDING SITE; CELL LINE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION; RNA INTERFERENCE; VIROLOGY; VIRUS CAPSID;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BETA KARYOPHERINS; BINDING SITES; CAPSID; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; INDOLES; MACROPHAGES; MOLECULAR CHAPERONES; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; NUCLEAR PORE COMPLEX PROTEINS; PHENYLALANINE; PROTEIN BINDING; PROTEIN CONFORMATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84938937756     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00340-15     Document Type: Article

References (57)

1. Sundquist WI, Krausslich HG. 2012. HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med 2:a006924. http://dx.doi.org/10.1101/cshperspect.a006924.
2. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853. http://dx.doi.org/10.1038/nature02343.
3. Sayah DM, Sokolskaja E, Berthoux L, Luban J. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573. http://dx.doi.org/10.1038/nature02777.
4. Nisole S, Lynch C, Stoye JP, Yap MW. 2004. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A 101:13324-13328. http://dx.doi.org/10.1073/pnas.0404640101.
5. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, Hue S, Barclay WS, Schulz R, Malim MH. 2013. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 502:559-562. http://dx.doi.org/10.1038/nature12542.
6. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, Cen S, Guo F, Liang C. 2013. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 14:398-410. http://dx.doi.org/10.1016/j.chom.2013.08.015.
7. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, Schoggins JW, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD. 2013. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502: 563-566. http://dx.doi.org/10.1038/nature12653.
8. Fribourgh JL, Nguyen HC, Matreyek KA, Alvarez FJ, Summers BJ, Dewdney TG, Aiken C, Zhang P, Engelman A, Xiong Y. 2014. Structural insight into HIV-1 restriction by MxB. Cell Host Microbe 16:627-638. http://dx.doi.org/10.1016/j.chom.2014.09.021.
9. Pornillos O, Ganser-Pornillos BK, Yeager M. 2011. Atomic-level modelling of the HIV capsid. Nature 469:424-427. http://dx.doi.org/10.1038/nature09640.
10. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, Stout CD, Sundquist WI, Hill CP, Yeager M. 2009. X-ray structures of the hexameric building block of the HIV capsid. Cell 137:1282-1292. http://dx.doi.org/10.1016/j.cell.2009.04.063.
11. Zhao G, Perilla JR, Yufenyuy EL, Meng X, Chen B, Ning J, Ahn J, Gronenborn AM, Schulten K, Aiken C, Zhang P. 2013. Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamics. Nature 497:643-646. http://dx.doi.org/10.1038/nature12162.
12. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. 1993. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B Cell 73:1067-1078.
13. Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, Vandegraaff N, Baumann JG, Wang R, Yuen W, Takemura T, Shelton K, Taniuchi I, Li Y, Sodroski J, Littman DR, Coffin JM, Hughes SH, Unutmaz D, Engelman A, KewalRamani VN. 2010. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7:221-233. http://dx.doi.org/10.1016/j.chom.2010.02.007.
14. Krishnan L, Matreyek KA, Oztop I, Lee K, Tipper CH, Li X, Dar MJ, Kewalramani VN, Engelman A. 2010. The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase. J Virol 84:397-406. http://dx.doi.org/10.1128/JVI.01899-09.
15. Matreyek KA, Engelman A. 2011. The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol 85:7818-7827. http://dx.doi.org/10.1128/JVI.00325-11.
16. Valle-Casuso JC, Di Nunzio F, Yang Y, Reszka N, Lienlaf M, Arhel N, Perez P, Brass AL, Diaz-Griffero F. 2012. TNPO3 is required for HIV-1 replication after nuclear import but prior to integration and binds the HIV-1 core. J Virol 86:5931-5936. http://dx.doi.org/10.1128/JVI.00451-12.
17. Di Nunzio F, Fricke T, Miccio A, Valle-Casuso JC, Perez P, Souque P, Rizzi E, Severgnini M, Mavilio F, Charneau P, Diaz-Griffero F. 2013. Nup153 and Nup98 bind the HIV-1 core and contribute to the early steps of HIV-1 replication. Virology 440:8-18. http://dx.doi.org/10.1016/j.virol.2013.02.008.
18. Ocwieja KE, Brady TL, Ronen K, Huegel A, Roth SL, Schaller T, James LC, Towers GJ, Young JA, Chanda SK, Konig R, Malani N, Berry CC, Bushman FD. 2011. HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog 7:e1001313. http://dx.doi.org/10.1371/journal.ppat.1001313.
19. Schaller T, Ocwieja KE, Rasaiyaah J, Price AJ, Brady TL, Roth SL, Hue S, Fletcher AJ, Lee K, KewalRamani VN, Noursadeghi M, Jenner RG, James LC, Bushman FD, Towers GJ. 2011. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog 7:e1002439. http://dx.doi.org/10.1371/journal.ppat.1002439.
20. Zhou L, Sokolskaja E, Jolly C, James W, Cowley SA, Fassati A. 2011. Transportin 3 promotes a nuclear maturation step required for efficient HIV-1 integration. PLoS Pathog 7:e1002194. http://dx.doi.org/10.1371/journal.ppat.1002194.
21. Henning MS, Dubose BN, Burse MJ, Aiken C, Yamashita M. 2014. In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects. PLoS Pathog 10:e1003868. http://dx.doi.org/10.1371/journal.ppat.1003868.
22. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, Jacques DA, Selwood DL, James LC, Noursadeghi M, Towers GJ. 2013. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 503:402-405. http://dx.doi.org/10.1038/nature12769.
23. Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, El Marjou A, Lacabaratz C, Lelievre JD, Manel N. 2013. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity 39:1132-1142. http://dx.doi.org/10.1016/j.immuni.2013.11.002.
24. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, Sun Y, Huang M, Summers MF. 2003. Antiviral inhibition of the HIV-1 capsid protein. J Mol Biol 327:1013-1020. http://dx.doi.org/10.1016/S0022-2836(03)00289-4.
25. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, Robinson H, Sundquist WI, Summers MF, Hill CP. 2007. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol 373:355-366. http://dx.doi.org/10.1016/j.jmb.2007.07.070.
26. Sticht J, Humbert M, Findlow S, Bodem J, Muller B, Dietrich U, Werner J, Krausslich HG. 2005. A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 12:671-677. http://dx.doi.org/10.1038/nsmb964.
27. Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK. 2008. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol 378:565-580. http://dx.doi.org/10.1016/j.jmb.2008.02.066.
28. Lamorte L, Titolo S, Lemke CT, Goudreau N, Mercier JF, Wardrop E, Shah VB, von Schwedler UK, Langelier C, Banik SS, Aiken C, Sundquist WI, Mason SW. 2013. Discovery of novel small molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother 57:4622-4631. http://dx.doi.org/10.1128/AAC.00985-13.
29. Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J, Ciaramella G, Isaacson J, Jackson L, Hunt R, Kjerrstrom A, Nieman JA, Patick AK, Perros M, Scott AD, Whitby K, Wu H, Butler SL. 2010. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog 6:e1001220. http://dx.doi.org/10.1371/journal.ppat.1001220.
30. Price AJ, Jacques DA, McEwan WA, Fletcher AJ, Essig S, Chin JW, Halambage UD, Aiken C, James LC. 2014. Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS Pathog 10:e1004459. http://dx.doi.org/10.1371/journal.ppat.1004459.
31. Bhattacharya A, Alam SL, Fricke T, Zadrozny K, Sedzicki J, Taylor AB, Demeler B, Pornillos O, Ganser-Pornillos BK, Diaz-Griffero F, Ivanov DN, Yeager M. 2014. Structural basis of HIV-1 capsid recognition by PF74 and CPSF6. Proc Natl Acad Sci U S A 111:18625-18630. http://dx.doi.org/10.1073/pnas.1419945112.
32. Shi J, Zhou J, Shah VB, Aiken C, Whitby K. 2011. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 85:542-549. http://dx.doi.org/10.1128/JVI.01406-10.
33. Fricke T, Buffone C, Opp S, Valle-Casuso J, Diaz-Griffero F. 2014. BI-2 destabilizes HIV-1 cores during infection and prevents binding of CPSF6 to the HIV-1 capsid. Retrovirology 11:120. http://dx.doi.org/10.1186/s12977-014-0120-x.
34. Shi J, Zhou J, Halambage UD, Shah VB, Burse MJ, Wu H, Blair WS, Butler SL, Aiken C. 2015. Compensatory substitutions in the HIV-1 capsid reduce the fitness cost associated with resistance to a capsidtargeting small-molecule inhibitor. J Virol 89:208-219. http://dx.doi.org/10.1128/JVI.01411-14.
35. Gallay P, Hope T, Chin D, Trono D. 1997. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/ karyopherin pathway. Proc Natl Acad Sci U S A 94:9825-9830. http://dx.doi.org/10.1073/pnas.94.18.9825.
36. Pornillos O, Ganser-Pornillos BK, Banumathi S, Hua Y, Yeager M. 2010. Disulfide bond stabilization of the hexameric capsomer of human immunodeficiency virus. J Mol Biol 401:985-995. http://dx.doi.org/10.1016/j.jmb.2010.06.042.
37. Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, KewalRamani VN, Chin JW, Towers GJ, James LC. 2012. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog 8:e1002896. http://dx.doi.org/10.1371/journal.ppat.1002896.
38. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871-875. http://dx.doi.org/10.1038/nbt0997-871.
39. Yee JK, Friedmann T, Burns JC. 1994. Generation of high-titer pseudotyped retroviral with very broad host range. Methods Cell Biol 43: 99-112.
40. Shah VB, Shi J, Hout DR, Oztop I, Krishnan L, Ahn J, Shotwell MS, Engelman A, Aiken C. 2013. The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. J Virol 87:422-432. http://dx.doi.org/10.1128/JVI.07177-11.
41. Anonymous. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763. http://dx.doi.org/10.1107/S0907444994003112.
42. Meehan AM, Saenz DT, Guevera R, Morrison JH, Peretz M, Fadel HJ, Hamada M, van Deursen J, Poeschla EM. 2014. A cyclophilin homology domain-independent role for Nup358 in HIV-1 infection. PLoS Pathog 10:e1003969. http://dx.doi.org/10.1371/journal.ppat.1003969.
43. De Iaco A, Santoni F, Vannier A, Guipponi M, Antonarakis S, Luban J. 2013. TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology 10:20. http://dx.doi.org/10.1186/1742-4690-10-20.
44. Veillette M, Bichel K, Pawlica P, Freund SM, Plourde MB, Pham QT, Reyes-Moreno C, James LC, Berthoux L. 2013. The V86M mutation in HIV-1 capsid confers resistance to TRIM5alpha by abrogation of cyclophilin A-dependent restriction and enhancement of viral nuclear import. Retrovirology 10:25. http://dx.doi.org/10.1186/1742-4690-10-25.
45. Peng K, Muranyi W, Glass B, Laketa V, Yant SR, Tsai L, Cihlar T, Muller B, Krausslich HG. 2014. Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid. eLife 3:e04114. http://dx.doi.org/10.7554/eLife.04114.
46. Zhang R, Mehla R, Chauhan A. 2010. Perturbation of host nuclear membrane component RanBP2 impairs the nuclear import of human immunodeficiency virus-1 preintegration complex (DNA). PLoS One 5:e15620. http://dx.doi.org/10.1371/journal.pone.0015620.
47. Matreyek KA, Yucel SS, Li X, Engelman A. 2013. Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog 9:e1003693. http://dx.doi.org/10.1371/journal.ppat.1003693.
48. Yang R, Shi J, Byeon I-JL, Ahn J, Sheehan JH, Meiler J, Gronenborn AM, Aiken C. 2012. Identification of second-site suppressors of human immunodeficiency virus type 1 CA mutants: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology 9:30. http://dx.doi.org/10.1186/1742-4690-9-30.
49. Ambrose Z, Lee K, Ndjomou J, Xu H, Oztop I, Matous J, Takemura T, Unutmaz D, Engelman A, Hughes SH, KewalRamani VN. 2012. Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilinA dependence and impairs macrophage infection. J Virol 86:4708-4714. http://dx.doi.org/10.1128/JVI.05887-11.
50. Ammaranond P, Sanguansittianan S. 2012. Mechanism of HIV antiretroviral drugs progress toward drug resistance. Fundam Clin Pharmacol 26:146-161. http://dx.doi.org/10.1111/j.1472-8206.2011.01009.x.
51. Arts EJ, Hazuda DJ. 2012. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2:a007161. http://dx.doi.org/10.1101/cshperspect.a007161.
52. Li G, Verheyen J, Rhee SY, Voet A, Vandamme AM, Theys K. 2013. Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology 10:126. http://dx.doi.org/10.1186/1742-4690-10-126.
53. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM, Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM. 2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 81:12382-12393. http://dx.doi.org/10.1128/JVI.01543-07.
54. Mosser AG, Sgro JY, Rueckert RR. 1994. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J Virol 68:8193-8201.
55. Mosser AG, Rueckert RR. 1993. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J Virol 67:1246-1254.
56. Aberham C, Weber S, Phares W. 1996. Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol 70:3536-3544.
57. Braaten D, Aberham C, Franke EK, Yin L, Phares W, Luban J. 1996. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A J Virol 70:5170-5176.